One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Frequency and Outcomes of Periprocedural MI in Patients With Chronic Coronary Syndromes Undergoing PCI
YasushiUekiMD, PhDaTatsuhikoOtsukaMDaSarahBärMDaKostantinos C.KoskinasMD, MScaDikHegPhDbJonasHänerMDaGeorge C.M.SiontisMD, PhDaFabienPrazMDaLukasHunzikerMDaJonasLanzMD, MScaStefanStorteckyMD, MPHaThomasPilgrimMD, MScaSylvainLosdatPhDbStephanWindeckerMDaLorenzRäberMD, PhDa
doi : 10.1016/j.jacc.2021.11.047
Volume 79, Issue 6, 15 February 2022, Pages 513-526
Definitions of periprocedural myocardial infarction (MI) differ with respect to biomarker threshold as well as ancillary criteria for myocardial ischemia and are limited in terms of validation.
Periprocedural MI as an Endpoint in Clinical Trials: A Proposed Path Forward∗
Cian P.McCarthyMB, BCh, BAOaJames L.JanuzziJr.MDab
doi : 10.1016/j.jacc.2021.11.046
Volume 79, Issue 6, 15 February 2022, Pages 527-529
Discordance Between Standard Equations for Determination of LDL Cholesterol in Patients With Atherosclerosis
AparnaSajjaMDabHsin-FangLiPhDcKateri J.SpinelliPhDcRoger S.BlumenthalMDbSalim S.ViraniMD, PhDdSeth S.MartinMD, MHSbTy J.GluckmanMD, MHAbc
doi : 10.1016/j.jacc.2021.11.042
Volume 79, Issue 6, 15 February 2022, Pages 530-541
Accurate estimation of low-density lipoprotein cholesterol (LDL-C) is important for guiding cholesterol-lowering therapy. Different methods currently exist to estimate LDL-C.
LDL-C Estimation: The Perils of Living With Imperfection∗
Kevin C.MakiPhDabJelani K.GrantMDcCarl E.OrringerMDc
doi : 10.1016/j.jacc.2021.12.005
Volume 79, Issue 6, 15 February 2022, Pages 542-544
Lipoprotein(a) and Body Mass Compound the Risk of Calcific Aortic Valve Disease
MortenKaltoftMDabcAnneLangstedMD, PhDabcShoaibAfzalMD, PhD, DMScabcPia R.KamstrupMD, PhDabBørge G.NordestgaardMD, DMScabc
doi : 10.1016/j.jacc.2021.11.043
Volume 79, Issue 6, 15 February 2022, Pages 545-558
High plasma lipoprotein(a) and high body mass index are both causal risk factors for calcific aortic valve disease.
The Lp(a)/BMI Gradient in Osteocardiology: The Copenhagen Connection∗
Nalini M.RajamannanMD
doi : 10.1016/j.jacc.2021.11.044
Volume 79, Issue 6, 15 February 2022, Pages 559-561
A Score to Assess Mortality After Percutaneous Mitral Valve Repair
SergioRaposeiras-RoubinMD, PhDaMariannaAdamoMDbXavierFreixaMD, PhDcDabitArzamendiMD, PhDdTomasBenito-GonzálezMDeAntonioMontefuscoMD, PhDfIsaacPascualMD, PhDgLuisNombela-FrancoMD, PhDhJosepRodes-CabauMD, PhDiMonyShuvyMD, PhDjAntonioPortolés-HernándezMD, PhDkCosmoGodinoMD, PhDlBereniceCaneiro-QueijaMDaLauraLupiMDbAnderRegueiroMD, PhDcChin HionLiMD, PhDdFelipeFernández-VázquezMD, PhDeSimoneFreaMD, PhDf…RodrigoEstévez-LoureiroMD, PhDa
doi : 10.1016/j.jacc.2021.11.041
Volume 79, Issue 6, 15 February 2022, Pages 562-573
Risk stratification for transcatheter edge-to-edge mitral valve repair (TEER) is paramount in the decision-making process for treating severe mitral regurgitation (MR).
Risk Stratification of Patients Undergoing Mitral TEER∗
MohamadAlkhouliMDaIgor F.PalaciosMDbHaniJneidMDc
doi : 10.1016/j.jacc.2021.12.003
Volume 79, Issue 6, 15 February 2022, Pages 574-576
Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications: JACC State-of-the-Art Review
Jacqueline T.VuongMDaAshley F.Stein-MerlobMDbArashNayeriMDbTamerSallamMD, PHDbTomas G.NeilanMD, MPHcEric H.YangMDbd
doi : 10.1016/j.jacc.2021.11.048
Volume 79, Issue 6, 15 February 2022, Pages 577-593
Immune checkpoint inhibitor therapy has revolutionized the treatment of advanced malignancies in recent years. Numerous reports have detailed the myriad of possible adverse inflammatory effects of immune checkpoint therapies, including within the cardiovascular system. However, these reports have been largely limited to myocarditis. The critical role of inflammation and adaptive immunity in atherosclerosis has been well characterized in preclinical studies, and several emerging clinical studies indicate a potential role of immune checkpoint targeting therapies in the development and exacerbation of atherosclerosis. In this review, we provide an overview of the role of T-cell immunity in atherogenesis and describe the molecular effects and clinical associations of both approved and investigational immune checkpoint therapy on atherosclerosis. We also highlight the role of cholesterol metabolism in oncogenesis and discuss the implications of these associations on future treatment and monitoring of atherosclerotic cardiovascular disease in the oncologic population receiving immune checkpoint therapy.
Echocardiographic Deformation Imaging for Early Detection of Genetic Cardiomyopathies: JACC Review Topic of the Week
KarimTahaMDab∗Feddo P.KirkelsMDabc∗Arco J.TeskeMD, PhDaFolkert W.AsselbergsMD, PhDadeJ. Petervan TintelenMD, PhDfPieter A.DoevendansMD, PhDabgShelbyKuttyMD, PhDhKristina H.HaugaaMD, PhDciMaarten J.CramerMD, PhDa
doi : 10.1016/j.jacc.2021.11.045
Volume 79, Issue 6, 15 February 2022, Pages 594-608
Clinical screening of the relatives of patients with genetic cardiomyopathies is challenging, as they often lack detectable cardiac abnormalities at presentation. Life-threatening adverse events can already occur in these early stages of disease, so sensitive tools to reveal the earliest signs of disease are needed. The utility of echocardiographic deformation imaging for early detection has been explored for this population in multiple studies but has not been broadly implemented in clinical practice. The authors discuss contemporary evidence on the utility of deformation imaging in relatives of patients with genetic cardiomyopathies. The available body of data shows that deformation imaging reveals early disease-specific abnormalities in dilated cardiomyopathy, hypertrophic cardiomyopathy, and arrhythmogenic cardiomyopathy. Deformation imaging seems promising to enhance the screening and follow-up protocols in relatives, and the authors propose measures to accelerate its implementation in clinical care.
Training in Critical Care Cardiology Within Critical Care Medicine Fellowship: A Novel Pathway
Connor G.O’BrienMDaChristopher F.BarnettMD, MPHaDavid M.DudzinskiMD, JDbPablo A.SanchezMDcJason N.KatzMD, MHSdJohn G.HaroldMDeErin K.HennesseyMDfPaul K.MohabirMDg
doi : 10.1016/j.jacc.2021.12.009
Volume 79, Issue 6, 15 February 2022, Pages 609-613
Urban-Rural Disparity Trends in Aortic Aneurysm Mortality in the United States, 1999-2019
Author links open overlay panelKeerat RaiAhujaMDAnasQatananiBSAbdul MannanKhan MinhasMDRobert W.ArissBSAsifMahmoodMDSatish KumarAhujaMBBSRohitVyasMDSalikNazirMD
doi : 10.1016/j.jacc.2021.12.004
Volume 79, Issue 6, 15 February 2022, Pages 614-616
